Search
COSENTYX 150 MG, Solution injectable en seringue préremplie
Details
| --- | Description |
|---|---|
| Pack | Pack de 2 |
| Strength (Dosage) | 150 MG |
| Laboratory | NOVARTIS PHARMA MAROC |
| Ingredients | Sécukinumab |
| Therapeutic class | Immunosuppresseur, anticorps monoclonal humain (anti-IL-17A) |
| ATC code | L04AC10 |
| PPH | $1,139.70 |
| PPV | $1,161.70 |
| Refundable | Yes |
| Refund base | $1,161.70 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Medication |
| Uses | - Spondylite ankylosante sévère chez les patients adultes qui ont répondu insuffisamment au traitement conventionnel. - Arthrite psoriasique active, seul ou en association avec le méthotrexate chez les patients adultes qui ont répondu insuffisamment à un traitement précédent par antirhumatismaux modificateurs de la maladie. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem